Advertisement

Applied Microbiology and Biotechnology

, Volume 100, Issue 3, pp 1163–1181 | Cite as

The cystic fibrosis microbiome in an ecological perspective and its impact in antibiotic therapy

  • Andreia P. Magalhães
  • Nuno F. Azevedo
  • Maria O. Pereira
  • Susana P. LopesEmail author
Mini-Review

Abstract

The recent focus on the cystic fibrosis (CF) complex microbiome has led to the recognition that the microbes can interact between them and with the host immune system, affecting the disease progression and treatment routes. Although the main focus remains on the interactions between traditional pathogens, growing evidence supports the contribution and the role of emergent species. Understanding the mechanisms and the biological effects involved in polymicrobial interactions may be the key to improve effective therapies and also to define new strategies for disease control. This review focuses on the interactions between microbe–microbe and host–microbe, from an ecological point of view, discussing their impact on CF disease progression. There are increasing indications that these interactions impact the success of antimicrobial therapy. Consequently, a new approach where therapy is personalized to patients by taking into account their individual CF microbiome is suggested.

Keywords

Cystic fibrosis Ecological perspective Microbe–microbe interactions Microbe–host interactions Polymicrobial biofilms Antibiotic therapy 

Notes

Acknowledgments

The authors acknowledge the Portuguese Foundation for Science and Technology (FCT), the strategic funding of UID/BIO/04469/2013-CEB and UID/EQU/00511/2013-LEPABE units. This study was also supported by FCT and the European Community fund FEDER, through Program COMPETE, under the scope of the Projects “DNA mimics” PIC/IC/82815/2007, RECI/BBB-EBI/0179/2012 (FCOMP-01-0124-FEDER-027462), “BioHealth—Biotechnology and Bioengineering approaches to improve health quality”, Ref. NORTE-07-0124-FEDER-000027 and NORTE-07-0124-FEDER-000025—RL2_ Environment and Health, co-funded by the Programa Operacional Regional do Norte (ON.2 – O Novo Norte), QREN, FEDER. The authors also acknowledge the grant of Susana P. Lopes (SFRH/BPD/95616/2013) and of the COST-Action TD1004: Theragnostics for imaging and therapy.

Compliance with ethical standards

Declaration of interest

The authors report no declarations of interest.

References

  1. Alexander EH, Hudson MC (2001) Factors influencing the internalization of Staphylococcus aureus and impacts on the course of infections in humans. Appl Microbiol Biotechnol 56:361–366PubMedCrossRefGoogle Scholar
  2. Allen RC, Popat R, Diggle SP, Brown SP (2014) Targeting virulence: can we make evolution-proof drugs? Nat Rev Microbiol 12:300–308. doi: 10.1038/nrmicro3232 PubMedCrossRefGoogle Scholar
  3. Amin R, Dupuis A, Aaron SD, Ratjen F (2010) The effect of chronic infection with Aspergillus fumigatus on lung function and hospitalization in patients with cystic fibrosis. Chest 137:171–176. doi: 10.1378/chest.09-1103 PubMedCrossRefGoogle Scholar
  4. Andersen DH (1938) Cystic fibrosis of the pancreas and its relation to celiac disease. Am J Dis Child 56:344. doi: 10.1001/archpedi.1938.01980140114013 CrossRefGoogle Scholar
  5. Anderson GG, Kenney TF, Macleod DL, Henig NR, O’Toole GA (2013) Eradication of Pseudomonas aeruginosa biofilms on cultured airway cells by a fosfomycin/tobramycin antibiotic combination. Pathog Dis 67:39–45. doi: 10.1111/2049-632X.12015 PubMedCrossRefGoogle Scholar
  6. Anderson GG, O’Toole GA (2008) Innate and induced resistance mechanisms of bacterial biofilms. Curr Top Microbiol Immunol 322:85–105PubMedGoogle Scholar
  7. Anwar H, Dasgupta MK, Costerton JW (1990) Testing the susceptibility of bacteria in biofilms to antibacterial agents. Antimicrob Agents Chemother 34:2043–2046PubMedPubMedCentralCrossRefGoogle Scholar
  8. Bagge N, Schuster M, Hentzer M, Ciofu O, Givskov M, Greenberg EP, Høiby N (2004) Pseudomonas aeruginosa biofilms exposed to imipenem exhibit changes in global gene expression and beta-lactamase and alginate production. Antimicrob Agents Chemother 48:1175–1187PubMedPubMedCentralCrossRefGoogle Scholar
  9. Bakare N, Rickerts V, Bargon J, Just-Nübling G (2003) Prevalence of Aspergillus fumigatus and other fungal species in the sputum of adult patients with cystic fibrosis. Mycoses 46:19–23PubMedCrossRefGoogle Scholar
  10. Baldan R, Cigana C, Testa F, Bianconi I, De Simone M, Pellin D, Di Serio C, Bragonzi A, Cirillo DM (2014) Adaptation of Pseudomonas aeruginosa in cystic fibrosis airways influences virulence of Staphylococcus aureus in vitro and murine models of co-infection. PLoS One. doi: 10.1371/journal.pone.0089614 PubMedPubMedCentralGoogle Scholar
  11. Barton RC, Borman AM, Johnson EM, Houbraken J, Hobson RP, Denton M, Conway SP, Brownlee KG, Peckham D, Lee TWR (2010) Isolation of the fungus Geosmithia argillacea in sputum of people with cystic fibrosis. J Clin Microbiol 48:2615–2617. doi: 10.1128/JCM.00184-10
  12. Ben Dekhil SM, Peel MM, Lennox VA, Stackebrandt E, Sly LI (1997) Isolation of Lautropia mirabilis from sputa of a cystic fibrosis patient. J Clin Microbiol 35:1024–1026PubMedPubMedCentralGoogle Scholar
  13. Benedyk M, Byrne DP, Glowczyk I, Potempa J, Olczak M, Olczak T, Smalley JW (2015) Pyocycanin, a contributory factor in haem acquisition and virulence enhancement of Porphyromonas gingivalis in the lung. PLoS One 10:e0118319. doi: 10.1371/journal.pone.0118319 PubMedPubMedCentralCrossRefGoogle Scholar
  14. Bittar F, Richet H, Dubus J-C, Reynaud-Gaubert M, Stremler N, Sarles J, Raoult D, Rolain J-M (2008) Molecular detection of multiple emerging pathogens in sputa from cystic fibrosis patients. PLoS One 3:e2908. doi: 10.1371/journal.pone.0002908 PubMedPubMedCentralCrossRefGoogle Scholar
  15. Bittar F, Rolain J-M (2010) Detection and accurate identification of new or emerging bacteria in cystic fibrosis patients. Clin Microbiol Infect 16:809–820. doi: 10.1111/j.1469-0691.2010.03236.x PubMedCrossRefGoogle Scholar
  16. Bjarnsholt T, Jensen PØ, Fiandaca MJ, Pedersen J, Hansen CR, Andersen CB, Pressler T, Givskov M, Høiby N (2009) Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients. Pediatr Pulmonol 44:547–558. doi: 10.1002/ppul.21011 PubMedCrossRefGoogle Scholar
  17. Bodas M, Vij N (2010) The NF-kappaB signaling in cystic fibrosis lung disease: pathophysiology and therapeutic potential. Discov Med 9:346–356PubMedPubMedCentralGoogle Scholar
  18. Boon C, Deng Y, Wang L-H, He Y, Xu J-L, Fan Y, Pan SQ, Zhang L-H (2008) A novel DSF-like signal from Burkholderia cenocepacia interferes with Candida albicans morphological transition. Isme j 2:27–36. doi: 10.1038/ismej.2007.76 PubMedCrossRefGoogle Scholar
  19. Borriello G, Werner E, Roe F, Kim AM, Ehrlich GD, Stewart PS (2004) Oxygen limitation contributes to antibiotic tolerance of Pseudomonas aeruginosa in biofilms. Antimicrob Agents Chemother 48:2659–2664. doi: 10.1128/AAC.48.7.2659-2664.2004 PubMedPubMedCentralCrossRefGoogle Scholar
  20. Boucher RC (2007) Evidence for airway surface dehydration as the initiating event in CF airway disease. J Intern Med 261:5–16. doi: 10.1111/j.1365-2796.2006.01744.x PubMedCrossRefGoogle Scholar
  21. Boucher RC (2004) New concepts of the pathogenesis of cystic fibrosis lung disease. Eur Respir J 23:146–158PubMedCrossRefGoogle Scholar
  22. Bragonzi A, Farulla I, Paroni M, Twomey KB, Pirone L, Lorè NI, Bianconi I, Dalmastri C, Ryan RP, Bevivino A (2012) Modelling co-infection of the cystic fibrosis lung by Pseudomonas aeruginosa and Burkholderia cenocepacia reveals influences on biofilm formation and host response. PLoS One. doi: 10.1371/journal.pone.0052330 Google Scholar
  23. Burmølle M, Ren D, Bjarnsholt T, Sørensen SJ (2014) Interactions in multispecies biofilms: do they actually matter? Trends Microbiol 22:84–91. doi: 10.1016/j.tim.2013.12.004 PubMedCrossRefGoogle Scholar
  24. Burmølle M, Thomsen TR, Fazli M, Dige I, Christensen L, Homøe P, Tvede M, Nyvad B, Tolker-Nielsen T, Givskov M, Moser C, Kirketerp-Møller K, Johansen HK, Høiby N, Jensen PØ, Sørensen SJ, Bjarnsholt T (2010) Biofilms in chronic infections—a matter of opportunity—monospecies biofilms in multispecies infections. FEMS Immunol Med Microbiol 59:324–336. doi: 10.1111/j.1574-695X.2010.00714.x PubMedGoogle Scholar
  25. Burns JL, Emerson J, Stapp JR, Yim DL, Krzewinski J, Louden L, Ramsey BW, Clausen CR (1998) Microbiology of sputum from patients at cystic fibrosis centers in the United States. Clin Infect Dis 27:158–163PubMedCrossRefGoogle Scholar
  26. Butler WR, Sheils CA, Brown-Elliott BA, Charles N, Colin AA, Gant MJ, Goodill J, Hindman D, Toney SR, Wallace RJ, Yakrus MA (2007) First isolations of Segniliparus rugosus from patients with cystic fibrosis. J Clin Microbiol 45:3449–3452. doi: 10.1128/JCM.00765-07 PubMedPubMedCentralCrossRefGoogle Scholar
  27. Callaghan M, McClean S (2012) Bacterial host interactions in cystic fibrosis. Curr Opin Microbiol 15:71–77. doi: 10.1016/j.mib.2011.11.001 PubMedCrossRefGoogle Scholar
  28. Caraher E, Collins J, Herbert G, Murphy PG, Gallagher CG, Crowe MJ, Callaghan M, McClean S (2008) Evaluation of in vitro virulence characteristics of the genus Pandoraea in lung epithelial cells. J Med Microbiol 57:15–20. doi: 10.1099/jmm.0.47544-0 PubMedCrossRefGoogle Scholar
  29. Castellani C, Cuppens H, Macek M, Cassiman JJ, Kerem E, Durie P, Tullis E, Assael BM, Bombieri C, Brown A, Casals T, Claustres M, Cutting GR, Dequeker E, Dodge J, Doull I, Farrell P, Ferec C, Girodon E, Johannesson M, Kerem B, Knowles M, Munck A, Pignatti PF, Radojkovic D, Rizzotti P, Schwarz M, Stuhrmann M, Tzetis M, Zielenski J, Elborn JS (2008) Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. J Cyst Fibros 7:179–196. doi: 10.1016/j.jcf.2008.03.009 PubMedPubMedCentralCrossRefGoogle Scholar
  30. Chan C, Burrows LL, Deber CM (2005) Alginate as an auxiliary bacterial membrane: binding of membrane-active peptides by polysaccharides. J Pept Res 65:343–351. doi: 10.1111/j.1399-3011.2005.00217.x PubMedCrossRefGoogle Scholar
  31. Chattoraj SS, Murthy R, Ganesan S, Goldberg JB, Zhao Y, Hershenson MB, Sajjan US (2010) Pseudomonas aeruginosa alginate promotes Burkholderia cenocepacia persistence in cystic fibrosis transmembrane conductance regulator knockout mice. Infect Immun 78:984–993. doi: 10.1128/IAI.01192-09 PubMedPubMedCentralCrossRefGoogle Scholar
  32. Cimon B, Carrere J, Chazalette JP, Vinatier JF, Chabasse D, Bouchara JP (1999) Chronic airway colonization by Penicillium emersonii in a patient with cystic fibrosis. Med Mycol 37:291–293PubMedCrossRefGoogle Scholar
  33. Cimon B, Challier S, Béguin H, Carrère J, Chabasse D, Bouchara J-P (2005) Airway colonization by Acrophialophora fusispora in patients with cystic fibrosis. J Clin Microbiol 43:1484–1487. doi: 10.1128/JCM.43.3.1484-1487.2005 PubMedPubMedCentralCrossRefGoogle Scholar
  34. Coenye T, Goris J, Spilker T, Vandamme P, LiPuma JJ (2002) Characterization of unusual bacteria isolated from respiratory secretions of cystic fibrosis patients and description of Inquilinus limosus gen. nov., sp. nov. J Clin Microbiol 40:2062–2069PubMedPubMedCentralCrossRefGoogle Scholar
  35. Cohen-Cymberknoh M, Shoseyov D, Kerem E (2011) Managing cystic fibrosis: strategies that increase life expectancy and improve quality of life. Am J Respir Crit Care Med 183:1463–1471. doi: 10.1164/rccm.201009-1478CI PubMedCrossRefGoogle Scholar
  36. Costello A, Herbert G, Fabunmi L, Schaffer K, Kavanagh KA, Caraher EM, Callaghan M, McClean S (2011) Virulence of an emerging respiratory pathogen, genus Pandoraea, in vivo and its interactions with lung epithelial cells. J Med Microbiol 60:289–299. doi: 10.1099/jmm.0.022657-0 PubMedCrossRefGoogle Scholar
  37. Costerton JW (2001) Cystic fibrosis pathogenesis and the role of biofilms in persistent infection. Trends Microbiol 9:50–52PubMedCrossRefGoogle Scholar
  38. Cugini C, Calfee MW, Farrow JM, Morales DK, Pesci EC, Hogan DA (2007) Farnesol, a common sesquiterpene, inhibits PQS production in Pseudomonas aeruginosa. Mol Microbiol 65:896–906. doi: 10.1111/j.1365-2958.2007.05840.x PubMedCrossRefGoogle Scholar
  39. Dalton T, Dowd SE, Wolcott RD, Sun Y, Watters C, Griswold JA, Rumbaugh KP (2011) An in vivo polymicrobial biofilm wound infection model to study interspecies interactions. PLoS One 6:e27317. doi: 10.1371/journal.pone.0027317 PubMedPubMedCentralCrossRefGoogle Scholar
  40. Davis PB (2006) Cystic fibrosis since 1938. Am J Respir Crit Care Med 173:475–482. doi: 10.1164/rccm.200505-840OE PubMedCrossRefGoogle Scholar
  41. De Boeck K, Wilschanski M, Castellani C, Taylor C, Cuppens H, Dodge J, Sinaasappel M (2006) Cystic fibrosis: terminology and diagnostic algorithms. Thorax 61:627–635. doi: 10.1136/thx.2005.043539 PubMedPubMedCentralCrossRefGoogle Scholar
  42. Defontaine A, Zouhair R, Cimon B, Carrère J, Bailly E, Symoens F, Diouri M, Hallet J-N, Bouchara J-P (2002) Genotyping study of Scedosporium apiospermum isolates from patients with cystic fibrosis. J Clin Microbiol 40:2108–2114PubMedPubMedCentralCrossRefGoogle Scholar
  43. Delhaes L, Monchy S, Fréalle E, Hubans C, Salleron J, Leroy S, Prevotat A, Wallet F, Wallaert B, Dei-Cas E, Sime-Ngando T, Chabé M, Viscogliosi E (2012) The airway microbiota in cystic fibrosis: a complex fungal and bacterial community–implications for therapeutic management. PLoS One 7:e36313. doi: 10.1371/journal.pone.0036313 PubMedPubMedCentralCrossRefGoogle Scholar
  44. Döring G, Flume P, Heijerman H, Elborn JS (2012) Treatment of lung infection in patients with cystic fibrosis: current and future strategies. J Cyst Fibros 11:461–479. doi: 10.1016/j.jcf.2012.10.004 PubMedCrossRefGoogle Scholar
  45. Drevinek P, Mahenthiralingam E (2010) Burkholderia cenocepacia in cystic fibrosis: epidemiology and molecular mechanisms of virulence. Clin Microbiol Infect 16:821–830. doi: 10.1111/j.1469-0691.2010.03237.x PubMedCrossRefGoogle Scholar
  46. Duan K, Dammel C, Stein J, Rabin H, Surette MG (2003) Modulation of Pseudomonas aeruginosa gene expression by host microflora through interspecies communication. Mol Microbiol 50:1477–1491. doi: 10.1046/j.1365-2958.2003.03803.x PubMedCrossRefGoogle Scholar
  47. Essilfie A-T, Simpson JL, Dunkley ML, Morgan LC, Oliver BG, Gibson PG, Foster PS, Hansbro PM (2012) Combined Haemophilus influenzae respiratory infection and allergic airways disease drives chronic infection and features of neutrophilic asthma. Thorax 67:588–599. doi: 10.1136/thoraxjnl-2011-200160 PubMedCrossRefGoogle Scholar
  48. Farrell PM, Rosenstein BJ, White TB, Accurso FJ, Castellani C, Cutting GR, Durie PR, Legrys VA, Massie J, Parad RB, Rock MJ, Campbell PW (2008) Guidelines for diagnosis of cystic fibrosis in newborns through older adults: cystic fibrosis foundation consensus report. J Pediatr 153:S4–S14. doi: 10.1016/j.jpeds.2008.05.005 PubMedPubMedCentralCrossRefGoogle Scholar
  49. Faust K, Sathirapongsasuti JF, Izard J, Segata N, Gevers D, Raes J, Huttenhower C (2012) Microbial co-occurrence relationships in the human microbiome. PLoS Comput Biol 8:e1002606. doi: 10.1371/journal.pcbi.1002606 PubMedPubMedCentralCrossRefGoogle Scholar
  50. Fiel SB (2014) Aerosolized antibiotics in cystic fibrosis: an update. Expert Rev Respir Med 8:305–314. doi: 10.1586/17476348.2014.896205 PubMedCrossRefGoogle Scholar
  51. Folkesson A, Jelsbak L, Yang L, Johansen HK, Ciofu O, Høiby N, Molin S (2012) Adaptation of Pseudomonas aeruginosa to the cystic fibrosis airway: an evolutionary perspective. Nat Rev Microbiol 10:841–851. doi: 10.1038/nrmicro2907 PubMedCrossRefGoogle Scholar
  52. French GL (2010) The continuing crisis in antibiotic resistance. Int J Antimicrob Agents 36(Suppl 3):S3–S7. doi: 10.1016/S0924-8579(10)70003-0 PubMedCrossRefGoogle Scholar
  53. Friman VP, Ghoul M, Molin S, Johansen HK, Buckling A (2013) Pseudomonas aeruginosa adaptation to lungs of cystic fibrosis patients leads to lowered resistance to phage and protist enemies. PLoS One 8:1–9. doi: 10.1371/journal.pone.0075380 CrossRefGoogle Scholar
  54. Fugère A, Séguin DL, Mitchell G, Déziel E, Dekimpe V, Cantin AM, Frost E, Malouin F (2014) Interspecific small molecule interactions between clinical isolates of Pseudomonas aeruginosa and Staphylococcus aureus from adult cystic fibrosis patients. PLoS One. doi: 10.1371/journal.pone.0086705 PubMedPubMedCentralGoogle Scholar
  55. Fuqua WC, Winans SC, Greenberg EP (1994) Quorum sensing in bacteria: the LuxR-LuxI family of cell density-responsive transcriptional regulators. J Bacteriol 176:269–275PubMedPubMedCentralGoogle Scholar
  56. Gibson RL, Burns JL, Ramsey BW (2003) Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 168:918–951. doi: 10.1164/rccm.200304-505SO PubMedCrossRefGoogle Scholar
  57. Goss CH, Burns JL (2007) Exacerbations in cystic fibrosis. 1: epidemiology and pathogenesis. Thorax 62:360–367. doi: 10.1136/thx.2006.060889 PubMedPubMedCentralCrossRefGoogle Scholar
  58. Government US a (2013) Annual Data Report.Google Scholar
  59. Guss AM, Roeselers G, Newton ILG, Young CR, Klepac-Ceraj V, Lory S, Cavanaugh CM (2011) Phylogenetic and metabolic diversity of bacteria associated with cystic fibrosis. Isme j 5:20–29. doi: 10.1038/ismej.2010.88 PubMedPubMedCentralCrossRefGoogle Scholar
  60. Harris JK, De Groote MA, Sagel SD, Zemanick ET, Kapsner R, Penvari C, Kaess H, Deterding RR, Accurso FJ, Pace NR (2007) Molecular identification of bacteria in bronchoalveolar lavage fluid from children with cystic fibrosis. Proc Natl Acad Sci U S A 104:20529–20533. doi: 10.1073/pnas.0709804104 PubMedPubMedCentralCrossRefGoogle Scholar
  61. Harrison F (2007) Microbial ecology of the cystic fibrosis lung. Microbiology 153:917–923. doi: 10.1099/mic.0.2006/004077-0 PubMedCrossRefGoogle Scholar
  62. Hassett DJ, Cuppoletti J, Trapnell B, Lymar SV, Rowe JJ, Yoon SS, Hilliard GM, Parvatiyar K, Kamani MC, Wozniak DJ, Hwang SH, McDermott TR, Ochsner UA (2002) Anaerobic metabolism and quorum sensing by Pseudomonas aeruginosa biofilms in chronically infected cystic fibrosis airways: rethinking antibiotic treatment strategies and drug targets. Adv Drug Deliv Rev 54:1425–1443PubMedCrossRefGoogle Scholar
  63. Hassett DJ, Korfhagen TR, Irvin RT, Schurr MJ, Sauer K, Lau GW, Sutton MD, Yu H, Hoiby N (2010) Pseudomonas aeruginosa biofilm infections in cystic fibrosis: insights into pathogenic processes and treatment strategies. Expert Opin Ther Targets 14:117–130. doi: 10.1517/14728220903454988 PubMedCrossRefGoogle Scholar
  64. Hassett DJ, Sutton MD, Schurr MJ, Herr AB, Caldwell CC, Matu JO (2009) Pseudomonas aeruginosa hypoxic or anaerobic biofilm infections within cystic fibrosis airways. Trends Microbiol 17:130–138. doi: 10.1016/j.tim.2008.12.003 PubMedCrossRefGoogle Scholar
  65. Hauser AR, Jain M, Bar-Meir M, McColley SA (2011) Clinical significance of microbial infection and adaptation in cystic fibrosis. Clin Microbiol Rev 24:29–70. doi: 10.1128/CMR.00036-10 PubMedPubMedCentralCrossRefGoogle Scholar
  66. Hauser PM, Bernard T, Greub G, Jaton K, Pagni M, Hafen GM (2014) Microbiota present in cystic fibrosis lungs as revealed by whole genome sequencing. PLoS One 9:e90934. doi: 10.1371/journal.pone.0090934 PubMedPubMedCentralCrossRefGoogle Scholar
  67. Hickey PW, Sutton DA, Fothergill AW, Rinaldi MG, Wickes BL, Schmidt HJ, Walsh TJ (2009) Trichosporon mycotoxinivorans, a novel respiratory pathogen in patients with cystic fibrosis. J Clin Microbiol 47:3091–3097. doi: 10.1128/JCM.00460-09 PubMedPubMedCentralCrossRefGoogle Scholar
  68. Hoffman LR, Déziel E, D’Argenio DA, Lépine F, Emerson J, McNamara S, Gibson RL, Ramsey BW, Miller SI (2006) Selection for Staphylococcus aureus small-colony variants due to growth in the presence of Pseudomonas aeruginosa. Proc Natl Acad Sci U S A 103:19890–19895. doi: 10.1073/pnas.0606756104 PubMedPubMedCentralCrossRefGoogle Scholar
  69. Hogan DA, Vik Å, Kolter R (2004) A Pseudomonas aeruginosa quorum-sensing molecule influences Candida albicans morphology. Mol Microbiol 54:1212–1223. doi: 10.1111/j.1365-2958.2004.04349.x PubMedCrossRefGoogle Scholar
  70. Høiby N, Bjarnsholt T, Givskov M, Molin S, Ciofu O (2010a) Antibiotic resistance of bacterial biofilms. Int J Antimicrob Agents 35:322–332. doi: 10.1016/j.ijantimicag.2009.12.011 PubMedCrossRefGoogle Scholar
  71. Høiby N, Ciofu O, Bjarnsholt T (2010b) Pseudomonas aeruginosa biofilms in cystic fibrosis. Future Microbiol 5:1663–1674. doi: 10.2217/fmb.10.125 PubMedCrossRefGoogle Scholar
  72. Høiby N, Ciofu O, Johansen HK, Song Z, Moser C, Jensen PØ, Molin S, Givskov M, Tolker-Nielsen T, Bjarnsholt T (2011) The clinical impact of bacterial biofilms. Int J Oral Sci 3:55–65. doi: 10.4248/IJOS11026 PubMedPubMedCentralCrossRefGoogle Scholar
  73. Holcombe LJ, McAlester G, Munro CA, Enjalbert B, AJP B, N. A. R G, Ding C, Butler G, O’Gara F, Morrissey JP (2010) Pseudomonas aeruginosa secreted factors impair biofilm development in Candida albicans. Microbiology 156:1476–1485. doi: 10.1099/mic.0.037549-0 PubMedCrossRefGoogle Scholar
  74. Hoppentocht M, Hagedoorn P, Frijlink HW, de Boer AH (2014) Developments and strategies for inhaled antibiotic drugs in tuberculosis therapy: a critical evaluation. Eur J Pharm Biopharm 86:23–30. doi: 10.1016/j.ejpb.2013.10.019 PubMedCrossRefGoogle Scholar
  75. Huang YJ, Lynch SV (2011) The emerging relationship between the airway microbiota and chronic respiratory disease: clinical implications. Expert Rev Respir Med 5:809–821. doi: 10.1586/ers.11.76 PubMedPubMedCentralCrossRefGoogle Scholar
  76. Iaria M, Caccuri F, Apostoli P, Giagulli C, Pelucchi F, Padoan RF, Caruso A, Fiorentini S (2015) Detection of KI WU and Merkel cell polyomavirus in respiratory tract of cystic fibrosis patients. Clin Microbiol Infect 21:603.e9–603.e15. doi: 10.1016/j.cmi.2015.01.025 CrossRefGoogle Scholar
  77. Jacques I, Derelle J, Weber M, Vidailhet M (1998) Pulmonary evolution of cystic fibrosis patients colonized by Pseudomonas aeruginosa and/or Burkholderia cepacia. Eur J Pediatr 157:427–431PubMedCrossRefGoogle Scholar
  78. Kahl BC (2010) Impact of Staphylococcus aureus on the pathogenesis of chronic cystic fibrosis lung disease. Int J Med Microbiol 300:514–519. doi: 10.1016/j.ijmm.2010.08.002 PubMedCrossRefGoogle Scholar
  79. Kenney DMC, Brown KE, Allison DG (1995) Influence of Pseudomonas aeruginosa exoproducts on virulence factor production in Burkholderia cepacia : evidence of interspecies communication. Influ Pseudomonas aeruginosa Exoproducts Virulence Factor Prod Burkholderia Cepacia : Evid 177:6989–6992Google Scholar
  80. Kidd TJ, Ramsay KA, Hu H, Bye PTP, Elkins MR, Grimwood K, Harbour C, Marks GB, Nissen MD, Robinson PJ, Rose BR, Sloots TP, Wainwright CE, Bell SC (2009) Low rates of Pseudomonas aeruginosa misidentification in isolates from cystic fibrosis patients. J Clin Microbiol 47:1503–1509. doi: 10.1128/JCM.00014-09 PubMedPubMedCentralCrossRefGoogle Scholar
  81. Kim YJ, Paek SH, Jin S, Park BS, Ha UH (2014) A novel Pseudomonas aeruginosa-derived effector cooperates with flagella to mediate the upregulation of interleukin 8 in human epithelial cells. Microb Pathog 66:24–28. doi: 10.1016/j.micpath.2013.12.001
  82. King P (2011) Pathogenesis of bronchiectasis. Paediatr Respir Rev 12:104–110. doi: 10.1016/j.prrv.2010.10.011 PubMedCrossRefGoogle Scholar
  83. Kirkby S, Novak K, McCoy K (2011) Aztreonam (for inhalation solution) for the treatment of chronic lung infections in patients with cystic fibrosis: an evidence-based review. Core Evid 6:59–66. doi: 10.2147/CE.S11181 PubMedPubMedCentralCrossRefGoogle Scholar
  84. Kolak M, Karpati F, Monstein H-J, Jonasson J (2003) Molecular typing of the bacterial flora in sputum of cystic fibrosis patients. Int J Med Microbiol 293:309–317. doi: 10.1078/1438-4221-00265 PubMedCrossRefGoogle Scholar
  85. Korgaonkar A, Trivedi U, Rumbaugh KP, Whiteley M (2013) Community surveillance enhances Pseudomonas aeruginosa virulence during polymicrobial infection. Proc Natl Acad Sci U S A 110:1059–1064. doi: 10.1073/pnas.1214550110 PubMedPubMedCentralCrossRefGoogle Scholar
  86. Kotrange S, Kopp B, Akhter A, Abdelaziz D, Abu Khweek A, Caution K, Abdulrahman B, Wewers MD, McCoy K, Marsh C, Loutet SA, Ortega X, Valvano MA, Amer AO (2011) Burkholderia cenocepacia O polysaccharide chain contributes to caspase-1-dependent IL-1beta production in macrophages. J Leukoc Biol 89:481–488. doi: 10.1189/jlb.0910513 PubMedPubMedCentralCrossRefGoogle Scholar
  87. Kusenbach G, Skopnik H, Haase G, Friedrichs F, Döhmen H (1992) Exophiala dermatitidis pneumonia in cystic fibrosis. Eur J Pediatr 151:344–346PubMedCrossRefGoogle Scholar
  88. Lam J, Vaughan S, Parkins MD (2013) Tobramycin inhalation powder (TIP): an efficient treatment strategy for the management of chronic Pseudomonas aeruginosa infection in cystic fibrosis. Clin Med Insights Circ Respir Pulm Med 7:61–77. doi: 10.4137/CCRPM.S10592 PubMedPubMedCentralGoogle Scholar
  89. Lambert PA (2002) Mechanisms of antibiotic resistance in Pseudomonas aeruginosa. J R Soc Med 95(Suppl 4):22–26PubMedPubMedCentralGoogle Scholar
  90. Leão RS, Pereira RHV, Ferreira AG, Lima AN, Albano RM, Marques EA (2010) First report of Paenibacillus cineris from a patient with cystic fibrosis. Diagn Microbiol Infect Dis 66:101–103. doi: 10.1016/j.diagmicrobio.2009.06.011 PubMedCrossRefGoogle Scholar
  91. Leekha S, Terrell CL, Edson RS (2011) General principles of antimicrobial therapy. Mayo Clin Proc 86:156–167. doi: 10.4065/mcp.2010.0639 PubMedPubMedCentralCrossRefGoogle Scholar
  92. Lim YW, Evangelista JS, Schmieder R, Bailey B, Haynes M, Furlan M, Maughan H, Edwards R, Rohwer F, Conrad D, Forbes BA (2014) Clinical insights from metagenomic analysis of sputum samples from patients with cystic fibrosis. J Clin Microbiol 52:425–437. doi: 10.1128/JCM.02204-13 PubMedPubMedCentralCrossRefGoogle Scholar
  93. Lim YW, Schmieder R, Haynes M, Willner D, Furlan M, Youle M, Abbott K, Edwards R, Evangelista J, Conrad D, Rohwer F (2013) Metagenomics and metatranscriptomics: windows on CF-associated viral and microbial communities. J Cyst Fibros 12:154–164. doi: 10.1016/j.jcf.2012.07.009 PubMedPubMedCentralCrossRefGoogle Scholar
  94. Lopes SP, Azevedo NF, Pereira MO (2014a) Microbiome in cystic fibrosis: shaping polymicrobial interactions for advances in antibiotic therapy. Crit Rev Microbiol. doi: 10.3109/1040841X.2013.847898 PubMedGoogle Scholar
  95. Lopes SP, Azevedo NF, Pereira MO (2014b) Emergent bacteria in cystic fibrosis: in vitro biofilm formation and resilience under variable oxygen conditions. Biomed Res Int 2014:678301. doi: 10.1155/2014/678301 PubMedPubMedCentralGoogle Scholar
  96. Lopes SP, Ceri H, Azevedo NF, Pereira MO (2012) Antibiotic resistance of mixed biofilms in cystic fibrosis: impact of emerging microorganisms on treatment of infection. Int J Antimicrob Agents 40:260–263. doi: 10.1016/j.ijantimicag.2012.04.020 PubMedCrossRefGoogle Scholar
  97. Lorè NI, Cigana C, De Fino I, Riva C, Juhas M, Schwager S, Eberl L, Bragonzi A (2012) Cystic fibrosis-niche adaptation of Pseudomonas aeruginosa reduces virulence in multiple infection hosts. PLoS One 7:e35648. doi: 10.1371/journal.pone.0035648 PubMedPubMedCentralCrossRefGoogle Scholar
  98. Lumb R, Greville H, Martin J, Sangster N, Holmes M (2002) Nocardia asteroides isolated from three patients with cystic fibrosis. Eur J Clin Microbiol Infect Dis 21:230–233. doi: 10.1007/s10096-001-0687-8 PubMedCrossRefGoogle Scholar
  99. Lyczak JB, Cannon CL, Pier GB (2002) Lung infections associated with cystic fibrosis. Clin Microbiol Rev 15:194–222PubMedPubMedCentralCrossRefGoogle Scholar
  100. Lynch JP (2009) Burkholderia cepacia complex: impact on the cystic fibrosis lung lesion. Semin Respir Crit Care Med 30:596–610. doi: 10.1055/s-0029-1238918 PubMedCrossRefGoogle Scholar
  101. MacLeod DL, Barker LM, Sutherland JL, Moss SC, Gurgel JL, Kenney TF, Burns JL, Baker WR (2009) Antibacterial activities of a fosfomycin/tobramycin combination: a novel inhaled antibiotic for bronchiectasis. J Antimicrob Chemother 64:829–836. doi: 10.1093/jac/dkp282 PubMedPubMedCentralCrossRefGoogle Scholar
  102. Máiz L, Girón RM, Olveira C, Quintana E, Lamas A, Pastor D, Cantón R, Mensa J (2013) Inhaled antibiotics for the treatment of chronic bronchopulmonary Pseudomonas aeruginosa infection in cystic fibrosis: systematic review of randomised controlled trials. Expert Opin Pharmacother 14:1135–1149. doi: 10.1517/14656566.2013.790366 PubMedCrossRefGoogle Scholar
  103. Matos T, Cerar T, Praprotnik M, Krivec U, Pirš M (2015) First recovery of Rasamsonia argillacea species complex isolated in adolescent patient with cystic fibrosis in Slovenia—case report and review of literature. Mycoses 58:506–510. doi: 10.1111/myc.12340 PubMedCrossRefGoogle Scholar
  104. McCaughey G, Diamond P, Elborn JS, McKevitt M, Tunney MM (2013) Resistance development of cystic fibrosis respiratory pathogens when exposed to fosfomycin and tobramycin alone and in combination under aerobic and anaerobic conditions. PLoS One 8:e69763. doi: 10.1371/journal.pone.0069763 PubMedPubMedCentralCrossRefGoogle Scholar
  105. McCaughey G, McKevitt M, Elborn JS, Tunney MM (2012) Antimicrobial activity of fosfomycin and tobramycin in combination against cystic fibrosis pathogens under aerobic and anaerobic conditions. J Cyst Fibros 11:163–172. doi: 10.1016/j.jcf.2011.11.003 PubMedCrossRefGoogle Scholar
  106. Menuet M, Bittar F, Stremler N, Dubus J-C, Sarles J, Raoult D, Rolain J-M (2008) First isolation of two colistin-resistant emerging pathogens, Brevundimonas diminuta and Ochrobactrum anthropi, in a woman with cystic fibrosis: a case report. J Med Case Rep 2:373. doi: 10.1186/1752-1947-2-373 PubMedPubMedCentralCrossRefGoogle Scholar
  107. Moree WJ, Phelan VV, Wu C-H, Bandeira N, Cornett DS, Duggan BM, Dorrestein PC (2012) Interkingdom metabolic transformations captured by microbial imaging mass spectrometry. Proc Natl Acad Sci 109:13811–13816. doi: 10.1073/pnas.1206855109 PubMedPubMedCentralCrossRefGoogle Scholar
  108. Moskowitz SM, Foster JM, Emerson J, Burns JL (2004) Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis. J Clin Microbiol 42:1915–1922PubMedPubMedCentralCrossRefGoogle Scholar
  109. Mowat E, Rajendran R, Williams C, McCulloch E, Jones B, Lang S, Ramage G (2010) Pseudomonas aeruginosa and their small diffusible extracellular molecules inhibit Aspergillus fumigatus biofilm formation. FEMS Microbiol Lett 313:96–102. doi: 10.1111/j.1574-6968.2010.02130.x PubMedCrossRefGoogle Scholar
  110. Murray JL, Connell JL, Stacy A, Turner KH, Whiteley M (2014) Mechanisms of synergy in polymicrobial infections. J Microbiol 52:188–199. doi: 10.1007/s12275-014-4067-3 PubMedCrossRefGoogle Scholar
  111. Nagano Y, Millar BC, Goldsmith CE, Elborn JS, Rendall J, Moore JE (2007) Emergence of Scedosporium apiospermum in patients with cystic fibrosis. Arch Dis Child 92:607–607. doi: 10.1136/adc.2007.119503 PubMedPubMedCentralCrossRefGoogle Scholar
  112. Nixon GM, Armstrong DS, Carzino R, Carlin JB, Olinsky A, Robertson CF, Grimwood K (2001) Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis. J Pediatr 138:699–704. doi: 10.1067/mpd.2001.112897 PubMedCrossRefGoogle Scholar
  113. O’Neill K, Bradley JM, Johnston E, McGrath S, McIlreavey L, Rowan S, Reid A, Bradbury I, Einarsson G, Elborn JS, Tunney MM (2015) Reduced bacterial colony count of anaerobic bacteria is associated with a worsening in lung clearance index and inflammation in cystic fibrosis. PLoS One 10:e0126980. doi: 10.1371/journal.pone.0126980 PubMedPubMedCentralCrossRefGoogle Scholar
  114. Olesen HV, Nielsen LP, Schiotz PO (2006) Viral and atypical bacterial infections in the outpatient pediatric cystic fibrosis clinic. Pediatr Pulmonol 41:1197–1204. doi: 10.1002/ppul.20517 PubMedCrossRefGoogle Scholar
  115. Oliver A (2010) Mutators in cystic fibrosis chronic lung infection: prevalence, mechanisms, and consequences for antimicrobial therapy. Int J Med Microbiol 300:563–572. doi: 10.1016/j.ijmm.2010.08.009 PubMedCrossRefGoogle Scholar
  116. Patankar YR, Lovewell RR, Poynter ME, Jyot J, Kazmierczak BI, Berwin B (2013) Flagellar motility is a key determinant of the magnitude of the inflammasome response to Pseudomonas aeruginosa. Infect Immun 81:2043–2052. doi: 10.1128/IAI.00054-13 PubMedPubMedCentralCrossRefGoogle Scholar
  117. Peters BM, Jabra-Rizk MA, O’May GA, Costerton JW, Shirtliff ME, William Costerton J, Shirtliff ME (2012) Polymicrobial interactions: impact on pathogenesis and human disease. Clin Microbiol Rev 25:193–213. doi: 10.1128/CMR.00013-11 PubMedPubMedCentralCrossRefGoogle Scholar
  118. Pilkington R, Callaghan M, McClean S (2011) Activation of MMP-9 by human lung epithelial cells in response to the cystic fibrosis-associated pathogen Burkholderia cenocepacia reduced wound healing in. Am J Physiol - Lung Cell Mol Physiol 301:L575–L586. doi: 10.1152/ajplung.00226.2010 PubMedCrossRefGoogle Scholar
  119. Pompilio A, Crocetta V, De Nicola S, Verginelli F, Fiscarelli E, Di Bonaventura G (2015) Cooperative pathogenicity in cystic fibrosis: Stenotrophomonas maltophilia modulates Pseudomonas aeruginosa virulence in mixed biofilm. Front Microbiol 6:951. doi: 10.3389/fmicb.2015.00951 PubMedPubMedCentralCrossRefGoogle Scholar
  120. Price KE, Hampton TH, Gifford AH, Dolben EL, Hogan DA, Morrison HG, Sogin ML, O’Toole GA (2013) Unique microbial communities persist in individual cystic fibrosis patients throughout a clinical exacerbation. Microbiome 1:27. doi: 10.1186/2049-2618-1-27 PubMedPubMedCentralCrossRefGoogle Scholar
  121. Pustelny C, Komor U, Pawar V, Lorenz A, Bielecka A, Moter A, Gocht B, Eckweiler D, Müsken M, Grothe C, Lünsdorf H, Weiss S, Häussler S (2015) Contribution of veillonella parvula to Pseudomonas aeruginosa-mediated pathogenicity in a murine tumor model system. Infect Immun 83:417–429. doi: 10.1128/IAI.02234-14 PubMedPubMedCentralCrossRefGoogle Scholar
  122. Ramirez IA, Caverly LL, Kalikin LM, Goldsmith AM, Lewis TC, Burke DT, JJ LP, Sajjan US, Hershenson MB (2014) Differential responses to rhinovirus- and influenza-associated pulmonary exacerbations in patients with cystic fibrosis. Ann Am Thorac Soc 11:554–561. doi: 10.1513/AnnalsATS.201310-346OC PubMedPubMedCentralCrossRefGoogle Scholar
  123. Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Dřevínek P, Griese M, McKone EF, Wainwright CE, Konstan MW, Moss R, Ratjen F, Sermet-Gaudelus I, Rowe SM, Dong Q, Rodriguez S, Yen K, Ordoñez C, Elborn JS (2011) A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 365:1663–1672. doi: 10.1056/NEJMoa1105185 PubMedPubMedCentralCrossRefGoogle Scholar
  124. Rasko DA, Sperandio V (2010) Anti-virulence strategies to combat bacteria-mediated disease. Nat Rev Drug Discov 9:117–128. doi: 10.1038/nrd3013 PubMedCrossRefGoogle Scholar
  125. Razvi S, Quittell L, Sewall A, Quinton H, Marshall B, Saiman L (2009) Respiratory microbiology of patients with cystic fibrosis in the United States, 1995 to 2005. Chest 136:1554–1560. doi: 10.1378/chest.09-0132 PubMedCrossRefGoogle Scholar
  126. Rogers GB, Carroll MP, Serisier DJ, Hockey PM, Jones G, Bruce KD (2004) Characterization of bacterial community diversity in cystic fibrosis lung infections by use of 16s ribosomal DNA terminal restriction fragment length polymorphism profiling. J Clin Microbiol 42:5176–5183. doi: 10.1128/JCM.42.11.5176-5183.2004 PubMedPubMedCentralCrossRefGoogle Scholar
  127. Rogers GB, Hart CA, Mason JR, Hughes M, Walshaw MJ, Bruce KD (2003) Bacterial diversity in cases of lung infection in cystic fibrosis patients: 16S ribosomal DNA (rDNA) length heterogeneity PCR and 16S rDNA terminal restriction fragment length polymorphism profiling. J Clin Microbiol 41:3548–3558PubMedPubMedCentralCrossRefGoogle Scholar
  128. Rogers GB, Hoffman LR, Carroll MP, Bruce KD (2013) Interpreting infective microbiota: the importance of an ecological perspective. Trends Microbiol 21:271–276. doi: 10.1016/j.tim.2013.03.004 PubMedCrossRefGoogle Scholar
  129. Rowe SM, Miller S, Sorscher EJ (2005) Cystic fibrosis. N Engl J Med 352:1992–2001. doi: 10.1056/NEJMra043184 PubMedCrossRefGoogle Scholar
  130. Rüger M, Ackermann M, Reichl U (2014) Species-specific viability analysis of Pseudomonas aeruginosa, Burkholderia cepacia and Staphylococcus aureus in mixed culture by flow cytometry. BMC Microbiol 14:56. doi: 10.1186/1471-2180-14-56 PubMedPubMedCentralCrossRefGoogle Scholar
  131. Rutherford ST, Bassler BL (2012) Bacterial quorum sensing: its role in virulence and possibilities for its control. Cold Spring Harb Perspect Med. doi: 10.1101/cshperspect.a012427 PubMedPubMedCentralGoogle Scholar
  132. Schobert M, Jahn D (2010) Anaerobic physiology of Pseudomonas aeruginosa in the cystic fibrosis lung. Int J Med Microbiol 300:549–556. doi: 10.1016/j.ijmm.2010.08.007 PubMedCrossRefGoogle Scholar
  133. Sherrard LJ, Schaible B, Graham KA, McGrath SJ, McIlreavey L, Hatch J, Wolfgang MC, Muhlebach MS, Gilpin DF, Schneiders T, Elborn JS, Tunney MM (2014) Mechanisms of reduced susceptibility and genotypic prediction of antibiotic resistance in Prevotella isolated from cystic fibrosis (CF) and non-CF patients. J Antimicrob Chemother 69:2690–2698. doi: 10.1093/jac/dku192 PubMedPubMedCentralCrossRefGoogle Scholar
  134. Short FL, Murdoch SL, Ryan RP (2014) Polybacterial human disease: the ills of social networking. Trends Microbiol 22:508–516. doi: 10.1016/j.tim.2014.05.007 PubMedPubMedCentralCrossRefGoogle Scholar
  135. Sibley CD, Duan K, Fischer C, Parkins MD, Storey DG, Rabin HR, Surette MG (2008) Discerning the complexity of community interactions using a Drosophila model of polymicrobial infections. PLoS Pathog 4:e1000184. doi: 10.1371/journal.ppat.1000184 PubMedPubMedCentralCrossRefGoogle Scholar
  136. Sibley CD, Rabin H, Surette MG (2006) Cystic fibrosis: a polymicrobial infectious disease. Future Microbiol 1:53–61. doi: 10.2217/17460913.1.1.53 PubMedCrossRefGoogle Scholar
  137. Smyth AR, Smyth RL, Tong CY, Hart CA, Heaf DP (1995) Effect of respiratory virus infections including rhinovirus on clinical status in cystic fibrosis. Arch Dis Child 73:117–120PubMedPubMedCentralCrossRefGoogle Scholar
  138. Sousa AM, Pereira MO (2014) Pseudomonas aeruginosa diversification during infection development in cystic fibrosis lungs—a review. Pathog (Basel, Switzerland) 3:680–703. doi: 10.3390/pathogens3030680Google Scholar
  139. Sriramulu D (2013) Evolution and impact of bacterial drug resistance in the context of cystic fibrosis disease and nosocomial settings. Microbiol Insights 6:29–36. doi: 10.4137/MBI.S10792 PubMedPubMedCentralCrossRefGoogle Scholar
  140. Sriramulu DD, Lünsdorf H, Lam JS, Römling U (2005) Microcolony formation: a novel biofilm model of Pseudomonas aeruginosa for the cystic fibrosis lung. J Med Microbiol 54:667–676. doi: 10.1099/jmm.0.45969-0 PubMedCrossRefGoogle Scholar
  141. Standiford TJ, Kunkel SL, Basha MA, Chensue SW, Lynch JP, Toews GB, Westwick J, Strieter RM (1990) Interleukin-8 gene expression by a pulmonary epithelial cell line. A Model for Cytokine Networks in the Lung J Clin Invest 86:1945–1953. doi: 10.1172/JCI114928 Google Scholar
  142. Starner TD, Zhang N, Kim G, Apicella MA, McCray PB (2006) Haemophilus influenzae forms biofilms on airway epithelia: implications in cystic fibrosis. Am J Respir Crit Care Med 174:213–220. doi: 10.1164/rccm.200509-1459OC PubMedPubMedCentralCrossRefGoogle Scholar
  143. Stressmann FA, Rogers GB, van der Gast CJ, Marsh P, Vermeer LS, Carroll MP, Hoffman L, Daniels TWV, Patel N, Forbes B, Bruce KD (2012) Long-term cultivation-independent microbial diversity analysis demonstrates that bacterial communities infecting the adult cystic fibrosis lung show stability and resilience. Thorax 67:867–873. doi: 10.1136/thoraxjnl-2011-200932 PubMedCrossRefGoogle Scholar
  144. Traini D, Young PM (2009) Delivery of antibiotics to the respiratory tract: an update. Expert Opin Drug Deliv 6:897–905. doi: 10.1517/17425240903110710 PubMedCrossRefGoogle Scholar
  145. Treggiari MM, Rosenfeld M, Retsch-Bogart G, Gibson R, Ramsey B (2007) Approach to eradication of initial Pseudomonas aeruginosa infection in children with cystic fibrosis. Pediatr Pulmonol 42:751–756. doi: 10.1002/ppul.20665 PubMedCrossRefGoogle Scholar
  146. Tunney MM, Field TR, Moriarty TF, Patrick S, Doering G, Muhlebach MS, Wolfgang MC, Boucher R, Gilpin DF, McDowell A, Elborn JS (2008) Detection of anaerobic bacteria in high numbers in sputum from patients with cystic fibrosis. Am J Respir Crit Care Med 177:995–1001. doi: 10.1164/rccm.200708-1151OC PubMedCrossRefGoogle Scholar
  147. Tunney MM, Klem ER, Fodor AA, Gilpin DF, Moriarty TF, Mcgrath SJ, Muhlebach MS, Boucher RC, Cardwell C, Doering G, Elborn JS, Wolfgang MC (2011) Use of culture and molecular analysis to determine the effect of antibiotic treatment on microbial community diversity and abundance during exacerbation in patients with cystic fibrosis. Thorax 66:579–584. doi: 10.1136/thx.2010.137281 PubMedCrossRefGoogle Scholar
  148. Twomey KB, O’Connell OJ, McCarthy Y, Dow JM, O’Toole GA, Plant BJ, Ryan RP (2012) Bacterial cis-2-unsaturated fatty acids found in the cystic fibrosis airway modulate virulence and persistence of Pseudomonas aeruginosa. Isme j 6:939–950. doi: 10.1038/ismej.2011.167 PubMedPubMedCentralCrossRefGoogle Scholar
  149. Ulrich M, Beer I, Braitmaier P, Dierkes M, Kummer F, Krismer B, Schumacher U, Gräpler-Mainka U, Riethmüller J, Jensen PØ, Bjarnsholt T, Høiby N, Bellon G, Döring G (2010) Relative contribution of Prevotella intermedia and Pseudomonas aeruginosa to lung pathology in airways of patients with cystic fibrosis. Thorax 65:978–984. doi: 10.1136/thx.2010.137745 PubMedCrossRefGoogle Scholar
  150. van Westreenen M, Tiddens HAWM (2010) New antimicrobial strategies in cystic fibrosis. Paediatr Drugs 12:343–352. doi: 10.2165/11316240-000000000-00000 PubMedCrossRefGoogle Scholar
  151. Vettoretti L, Plésiat P, Muller C, El Garch F, Phan G, Attrée I, Ducruix A, Llanes C (2009) Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. Antimicrob Agents Chemother 53:1987–1997. doi: 10.1128/AAC.01024-08 PubMedPubMedCentralCrossRefGoogle Scholar
  152. Wei Q, Ma LZ (2013) Biofilm matrix and its regulation in Pseudomonas aeruginosa. Int J Mol Sci 14:20983–21005. doi: 10.3390/ijms141020983 PubMedPubMedCentralCrossRefGoogle Scholar
  153. Wellinghausen N, Wirths B, Poppert S (2006) Fluorescence in situ hybridization for rapid identification of Achromobacter xylosoxidans and Alcaligenes faecalis recovered from cystic fibrosis patients. J Clin Microbiol 44:3415–3417. doi: 10.1128/JCM.00508-06
  154. Whiteson KL, Meinardi S, Lim YW, Schmieder R, Maughan H, Quinn R, Blake DR, Conrad D, Rohwer F (2014) Breath gas metabolites and bacterial metagenomes from cystic fibrosis airways indicate active pH neutral 2,3-butanedione fermentation. Isme j 8:1247–1258. doi: 10.1038/ismej.2013.229 PubMedPubMedCentralCrossRefGoogle Scholar
  155. Wilschanski M (2013) Novel therapeutic approaches for cystic fibrosis. Discov Med 15:127–133PubMedGoogle Scholar
  156. Winstanley C, Fothergill JL (2009) The role of quorum sensing in chronic cystic fibrosis Pseudomonas aeruginosa infections. FEMS Microbiol Lett 290:1–9. doi: 10.1111/j.1574-6968.2008.01394.x PubMedCrossRefGoogle Scholar
  157. Worlitzsch D, Rintelen C, Böhm K, Wollschläger B, Merkel N, Borneff-Lipp M, Döring G (2009) Antibiotic-resistant obligate anaerobes during exacerbations of cystic fibrosis patients. Clin Microbiol Infect 15:454–460. doi: 10.1111/j.1469-0691.2008.02659.x PubMedCrossRefGoogle Scholar
  158. Worlitzsch D, Tarran R, Ulrich M, Schwab U, Cekici A, Meyer KC, Birrer P, Bellon G, Berger J, Weiss T, Botzenhart K, Yankaskas JR, Randell S, Boucher RC, Döring G (2002) Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J Clin Invest 109:317–325. doi: 10.1172/JCI13870 PubMedPubMedCentralCrossRefGoogle Scholar
  159. Yang JH, Spilker T, LiPuma JJ (2006) Simultaneous coinfection by multiple strains during Burkholderia cepacia complex infection in cystic fibrosis. Diagn Microbiol Infect Dis 54:95–98. doi: 10.1016/j.diagmicrobio.2005.08.020 PubMedCrossRefGoogle Scholar
  160. Yang L, Jelsbak L, Molin S (2011a) Microbial ecology and adaptation in cystic fibrosis airways. Environ Microbiol 13:1682–1689. doi: 10.1111/j.1462-2920.2011.02459.x PubMedCrossRefGoogle Scholar
  161. Yang L, Liu Y, Markussen T, Høiby N, Tolker-Nielsen T, Molin S (2011b) Pattern differentiation in co-culture biofilms formed by Staphylococcus aureus and Pseudomonas aeruginosa. FEMS Immunol Med Microbiol 62:339–347. doi: 10.1111/j.1574-695X.2011.00820.x PubMedCrossRefGoogle Scholar
  162. Yoon SS, Hennigan RF, Hilliard GM, Ochsner UA, Parvatiyar K, Kamani MC, Allen HL, DeKievit TR, Gardner PR, Schwab U, Rowe JJ, Iglewski BH, McDermott TR, Mason RP, Wozniak DJ, Hancock REW, Parsek MR, Noah TL, Boucher RC, Hassett DJ (2002) Pseudomonas aeruginosa anaerobic respiration in biofilms: relationships to cystic fibrosis pathogenesis. Dev Cell 3:593–603PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  • Andreia P. Magalhães
    • 1
  • Nuno F. Azevedo
    • 2
  • Maria O. Pereira
    • 1
  • Susana P. Lopes
    • 1
    Email author
  1. 1.CEB—Centre of Biological Engineering, LIBRO—Laboratório de Investigação em Biofilmes Rosário OliveiraUniversity of MinhoBragaPortugal
  2. 2.LEPABE—Laboratory for Process Engineering, Environment, Biotechnology and Energy, Department of Chemical Engineering, Faculty of EngineeringUniversity of PortoPortoPortugal

Personalised recommendations